

**COMMONWEALTH OF MASSACHUSETTS**  
**Board of Registration in Pharmacy**

**NOTICE OF THE REGULARLY SCHEDULED MEETING OF THE  
BOARD OF REGISTRATION IN PHARMACY**

**December 4, 2025**

*The regular session is open to the public by video or phone.*

**Join link:**

**<https://eohhs.webex.com/eohhs/j.php?MTID=mfc7a4afc28432853102ac228bb13014>**

**Webinar number:** 2536 460 3902

**Webinar password:** BOP123

**Join by phone:**

+1-617-315-0704 United States Toll (Boston)

+1-650-479-3208 United States Toll

*If you need reasonable accommodations in order to participate in the meeting, contact the DPH ADA Coordinator Stacy Hart, [Stacy.Hart@mass.gov](mailto:Stacy.Hart@mass.gov) or 857-274-1120 in advance of the meeting. While the Board will do its best to accommodate you, certain accommodation may require distinctive requests or the hiring of outside contractors and may not be available if requested immediately before the meeting.*

**Agenda**

<b>8:00</b>		<b>CALL TO ORDER</b>		<b>S. Ahmed</b>
<b>8:05</b>	<b>II</b>	<b>APPROVAL OF AGENDA</b>		
<b>8:10</b>	<b>III</b>	<b>APPROVAL OF BOARD MINUTES</b> <ul style="list-style-type: none"><li>• Draft of November 6, 2025, Regular Session Minutes</li></ul>		
<b>8:15</b>	<b>IV</b>	<b>REPORTS</b> <ul style="list-style-type: none"><li>• Applications approved pursuant to Licensure Policy 13-01</li><li>• Monthly report from Probation</li><li>• Board Delegated Review pursuant to Licensure Policy 14-02</li></ul>		

8:20	V	<p><b>FLEX</b></p> <ul style="list-style-type: none"> <li>• Election of Board Officers <ul style="list-style-type: none"> <li>○ Candidates for Secretary: Jules Dorgan</li> <li>○ Candidates for President-Elect: Timothy Fensky; Mark Sciaraffa</li> </ul> </li> <li>• Facility License renewals</li> <li>• NABP Executive Forum</li> <li>• 122<sup>nd</sup> NABP Annual Meeting- Boston May 12-15, 2026</li> <li>• New Board member announcement</li> </ul>																										
8:40	VI	<p><b>APPLICATIONS</b></p> <ul style="list-style-type: none"> <li>• Cure-Aid Pharmacy <ul style="list-style-type: none"> <li>○ New Retail Pharmacy; DSNE10000496</li> </ul> </li> <li>• Medwiz of Mass, LLC DS90404 <ul style="list-style-type: none"> <li>○ Petition for Waiver; DSPW100088</li> </ul> </li> <li>• Promise Pharmacy <ul style="list-style-type: none"> <li>○ Non-Resident - Sterile Compounding License; NDSNE97478SC</li> </ul> </li> <li>• XeCare LLC <ul style="list-style-type: none"> <li>○ Non-Resident Complex Non-Sterile; NDSNE62183NS</li> </ul> </li> <li>• Irene Darras; PH236553 - Reactivation</li> </ul>																										
9:45	VII	<p><b>FILE REVIEW</b></p> <table border="1"> <tr> <td>1</td><td>CASE-2025-2146</td><td>PHA-2025-0066</td><td>Apotheco Pharmacy Newton. LLC, DS90339</td></tr> <tr> <td>2</td><td>CASE-2025-1929</td><td>PHA-2025-0075</td><td>Empower Pharma, NO00019</td></tr> <tr> <td>3</td><td>CASE-2025-2346</td><td>PHA-2025-0085</td><td>West 35th Apothecary, NDS32013</td></tr> <tr> <td>4</td><td>CASE-2025-2624</td><td>PHA-2025-0094</td><td>Partners of MA, LLC, DS3419</td></tr> <tr> <td>5</td><td>CASE-2025-2304</td><td>PHA-2025-0072</td><td>CVS #209, DS3597</td></tr> <tr> <td>6</td><td>CASE-2025-2306</td><td>PHA-2025-0081</td><td>CVS #17655, DS89999</td></tr> </table>	1	CASE-2025-2146	PHA-2025-0066	Apotheco Pharmacy Newton. LLC, DS90339	2	CASE-2025-1929	PHA-2025-0075	Empower Pharma, NO00019	3	CASE-2025-2346	PHA-2025-0085	West 35th Apothecary, NDS32013	4	CASE-2025-2624	PHA-2025-0094	Partners of MA, LLC, DS3419	5	CASE-2025-2304	PHA-2025-0072	CVS #209, DS3597	6	CASE-2025-2306	PHA-2025-0081	CVS #17655, DS89999		
1	CASE-2025-2146	PHA-2025-0066	Apotheco Pharmacy Newton. LLC, DS90339																									
2	CASE-2025-1929	PHA-2025-0075	Empower Pharma, NO00019																									
3	CASE-2025-2346	PHA-2025-0085	West 35th Apothecary, NDS32013																									
4	CASE-2025-2624	PHA-2025-0094	Partners of MA, LLC, DS3419																									
5	CASE-2025-2304	PHA-2025-0072	CVS #209, DS3597																									
6	CASE-2025-2306	PHA-2025-0081	CVS #17655, DS89999																									
10:30	VIII	<p><b>EXECUTIVE SESSION</b></p> <p>The Board will meet in Executive Session as authorized pursuant to M.G.L. c. 30A, § 21(a)(1) for the purpose of discussing the reputation, character, physical condition, or mental health, rather than professional competence, of an individual, or to discuss the discipline or dismissal of, or complaints or charges brought against, a public officer, employee, staff member or individual. Specifically, to evaluate the Good Moral Character as required for registration for a pending applicant.</p>																										
11:00	IX	<b>ADJUDICATORY SESSION (M.G.L. c. 30A, § 18)</b>																										
11:15	X	<b>M.G.L. c. 112, § 65C SESSION</b>																										
12:30	XI	<b>ADJOURNMENT</b>																										

COMMONWEALTH OF MASSACHUSETTS  
BOARD OF REGISTRATION IN PHARMACY

MINUTES OF THE GENERAL SESSION  
Via Remote WebEx Meeting  
December 4, 2025

---

<b><u>Board Members Present</u></b>	<b><u>Board Members Not Present</u></b>
Sami Ahmed, PharmD., RPh, BCPS, BCSCP, President Saad Dinno, RPh, FACP/FACA, President-Elect Katie Thornell, RPh, MBA Mark Sciaraffa, CPhT, Secretary Caryn Belisle, RPh, MBA John Rocchio, RPh, PharmD Delilah Barnes, RPh Rita Morelli, PharmD, BCACP, RPh Frank Lombardo Stephanie Patel, MD, MBA, FFHPM, HMDC Timothy Fensky, RPh	Julie Dorgan, RN

**Board Staff Present**

Michael Godek, Executive Director  
Jacqueline Petrillo, PharmD, RPh, JD, Board Counsel  
Michelle Chan, RPh, Quality Assurance Pharmacist  
Richard Harris, Program Analyst  
Joanna Chow, Program Analyst  
Taylor Lee, Office Support Specialist  
Joanne Trifone, RPh, Director of Investigations  
Julienne Tran, PharmD, Investigator  
Gregory Melton, JD, PharmD, BCPS, Investigator  
Keith Johnstone, Compliance Officer  
David Sencabaugh  
Gayatri Ramasubramanian, Pharmacy Intern  
Madhurima Chowdhury, Pharmacy Intern

---

**TOPIC I.** Attendance by roll call:

**CALL TO ORDER 8:01 AM**

A quorum of the Board was present, established by roll call. President Sami Ahmed chaired the meeting and explained that the Board of Pharmacy was recording the meeting.

Roll call attendance: S. Ahmed, present; S. Dinno, present; Mark Sciaraffa, present; K. Thornell, present; C. Belisle, present; J. Rocchio, present; D. Barnes, present; R. Morelli, present; T. Fensky, present, S. Patel, F. Lombardo, present.

**Topic II.** **Approval of Agenda** **TIME 8:04 AM**

**Agenda: 12/04/25**

**DISCUSSION:** Deferred Applications: XeCare, LLC; Irene Darrass  
Deferred: CASE-202502304; PHS-2025-0072; CVS #209, DS3597

**ACTION:** Motion by R. MORELLI, seconded by D. BARNES and voted unanimously by those present to approve the agenda with the noted change by roll call vote.

---

**Topic III** **Approval of Board Minutes** **TIME: 8:05 AM**

**Minutes**

1. **Draft 11/06/25**

**Change:** None

**ACTION:** Motion by K. THORNELL seconded M. SCIARAFFA and voted to approve the regular session minutes of 11/6/2025 with no noted changes by roll call vote.

---

**Topic IV.** **REPORTS**

**Applications approved pursuant to Licensure Policy 13-01** **TIME: 8:04 AM**

**PRESENTED BY:** R. HARRIS

**DISCUSSION:** R. Harris reported a total of 30 Resident Change Pharmacist Manager of Record applications, 14 Non-resident Change Designated Pharmacist-in-Charge applications, and 2 facility closures that have been approved via Staff Action since the November 6<sup>th</sup> Board meeting.

So noted.

---

**Topic IV.** **REPORTS**

**Monthly Report from Probation** **TIME: 8:05 AM**

**PRESENTED BY:** R. HARRIS

**DISCUSSION:** R. Harris reported on one compliance monitoring case that has been closed since the last Board meeting.

So noted.

---

**Topic IV.****REPORTS****Monthly Report from BDCR pursuant to Policy 14-02****TIME: 8:05 AM****PRESENTED BY:** R. HARRIS

**DISCUSSION:** R. Harris reported one failure to meet Continuing Education requirements, which was closed with no discipline warranted and remediation completed. Additionally, there has been one instance of controlled substance loss since the last report, which resulted in a reprimand.

So noted.

---

**TOPIC V****FLEX****1. Election of Board Officers****TIME: 8:06 AM**

Candidate for Secretary: Julie Dorgan

Candidates for President-Elect: Timothy Fensky; Mark Sciaraffa

**Presented by:** M. CHAN**Discussion:** The final vote for Board officers for 2026 was held.**Action:** Vote by roll call by the majority of those present for T. FENSKY to be President-Elect for 2026.**Action:** Voted unanimously by roll call of those present for J. DORGAN to be Secretary for 2026.

---

**2. Facility License renewals****TIME: 8:18 AM****Presented by:** M. GODEK

**Discussion:** Reminder for all pharmacies to renew their licenses before 12/31/25. For any questions or problems, please email [Pharmacy.Admin@mass.gov](mailto:Pharmacy.Admin@mass.gov)

So noted.

---

**3. NABP Executive Forum****TIME: 8:18 AM****Presented by:** M. GODEK; J. PETRILLO; T. FENSKY

**Discussion:** Topics from the October 2025 executive forum included DSCSA, counterfeit drugs, Medspas, losses in transit, conflicts of interest, and recovery programs.

So noted.

---

**4. 122nd NABP Annual Meeting- Boston May 12-15, 2026**

**TIME: 8:22 AM**

**Presented by:** M. GODEK

**Discussion:** All are invited to attend the NABP annual meeting in Boston.

**So noted.**

---

**5. New Board member announcement**

**TIME: 8:22 AM**

**Presented by:** M. GODEK

**Discussion:** The Board welcomes Patricia Wolohan, NP, BLS, ACLS as the Public Member with experience in Health Care Delivery, Administration, or Consumer Advocacy.

**So noted.**

---

**VI:**

**APPLICATIONS**

- **Cure-Aid Pharmacy** **New Retail Pharmacy; DSNE10000496** **TIME: 8:27 AM**

**Represented by:** Aleksey Grokhотов, Ron Lanton

**Recusal:**

**Discussion:**

**[See Board packet]**

**Questions:**

- Will there be any change in the hours and MOR?
  - No, everything will stay the same
- Who is the current MOR in good standing
  - Her name is Robin, and yes she is in good standing

**Action:** D. BARNES made a motion to approve the new pharmacy application; seconded by S. DINNO and voted unanimously by roll call of those present to approve the motion.

---

- **Medwiz of Mass, LLC DS90404** **Petition for Waiver; DSPW100088** **TIME: 8:36 AM**

**Represented by:** Jeffrey Kehl

**Recusal:** T. Fensky

**Discussion:**

- What type of process validation has been done for this technology?

- This is approved in New Jersey. Pharmacists check the canisters and any care produced by that canister will have the pharmacists' name. We also do a 3% random check on the cards everyday, and it is less than 0.005% that a card is not caught by the system.
- Can you describe the process for how a pharmacist checks the canisters?
  - For new canisters, technicians will enter the drug name, lot, expiration, ndc, etc... And the pharmacist checks each of those fields after the technician. And the also do a thorough check of the canister to make sure here are no desiccants or different pills in there
  - For refills, the information is already in place, so they are checking the Lot and expiration, and then they check the canister to make sure there are no different pills
- Are these single-dose or multi-dose?
  - Single-dose only
- Are these processes all documented?
  - Yes
- Can you walk us through the verification process for prescriptions filled manually?
  - The label is produced, a technician fills it, a pharmacist verifies. We also implement a barcode system so when the medication is packed a sticker is produced and we use that the check as well.
  - We also use Frameworks where there are images of the pill and the pharmacist can also open it and see the medication.

**Waiver:**

**Medwiz of Mass, LLC (DS90404):**

Limited waiver for 247 CMR 9.04 (1) final dispensing process validation is not needed when using the DOSIS® medication adherence packaging machine after the pharmacist has reviewed the prescription and checked the stocked canisters. Pharmacists must randomly perform 5% verification check of the adherence cards. All other workflow processes not using the specified automation will require 100% pharmacist verification. Provide data submission with error metrics every 3 months for 1 year. Waiver valid for 1 year only. (re-evaluate at 1 year mark)

**Action:** D. BARNES made a motion to approve the limited waiver for 247 CMR 9.04(1) as written above; seconded by C. BELISLE and voted by roll call of those present to approve the motion.

Votes: J. Rocchio – Nay; M. Sciarfaffa – Ay; D. Barnes – Ay, R. Morelli – Ay, S. Patel – Ay, K. thornell – Ay, C. Belisle – Ay, S. Dinno – Ay; S. Ahmed – Ay.

- **Promise Pharmacy** TIME: 8:48 AM
- **Non-Resident - Sterile Compounding License; NDSNE97478SC**

**Represented by:** Mipal Patel, Smita Parmar

**Recusal:**

**Discussion:**

- Are you currently compounding commercially available GLP-1s?
  - We do not compound commercially available GLP-1s, we compound it with pyridoxine (Vitamin B6)

- Do you have studies or data backing this up? Or is this a prescriber preference?
  - We started as a prescriber preference and we have found that B6 helps with the nausea muscle mass loss. We do not have any clinical data it is prescriber preference.
- Where are you obtaining the prescriptions? Are you doing any campaigns?
  - We don't have any campaigns, we have previously worked with a lot of wellness doctors who prior to GLP-1s so we already had a relationship with the doctor. We don't have any one we work with specifically.
- As there is no clinical data supporting this formulation, if a doctor wants to write a prescription for a patient what do you provide doctors with?
  - We talk with the doctors and explain them that we have found that the Vitamin b6 helps with the nausea, and that there is information which shows that Vitamin B6 helps in treating nausea and morning sickness.
- Is the doctor aware of every item in the compounded products? Is there any clinically based data that can be provided to the doctors if they want to inquire about the ingredients or formula used?
  - We provide them standard clinical data but it is up to the doctor to decide what is best for the patient. The dosing comes from the manufacturer but the formulation data we provide comes from the master formula we use.
- Do you verify the patient doctor relationship?
  - When we work with the doctors we go over the details of what is required for these medications
- How many doctors do have writing for this GLP-1 and Vitamin B6 combination?
  - Over 100
- One of your forms says "bill office" can you explain what that means?
  - We bill the clinician office and they pass the costs onto the patients.
- That sounds like making prescriptions for office stock
  - All of our prescriptions are patient specific and the vast majority go to the patient, not the office. Every thing we do is patient specific, we calculate the dosing based on each specific patient.
- As you do not do marketing how would a doctor here in Massachusetts find out about Promis Pharmacy?
  - Word of mouth. One doctor tells another doctor.
- Are you currently shipping to Massachusetts?
  - For commercially available products and nonsterile compounding we are.
- In the Gates healthcare/NABP inspection report it states that at the time of inspection you weren't following USP <797> or USP <800> due to Florida law and that starting in November you would start being compliant. Can you explain that?
  - Currently we are 100% compliant starting November 1<sup>st</sup>.
- Are all bulk chemicals and substances compliant with the requirements of FD&C that they are safe to compound?
  - Yes any chemical or bulk substance that we use is compliant
- Are patients paying cash or does this go through insurance?
  - All cash, we do not have a contract with insurance
- Is the patient given the opportunity to receive this GLP-1 compound without the Vitamin b6?
  - If the doctor wants to order the commercially available drug we can get that for them, but we won't be able to bill insurance so we notify the patients of the pricing

- Do you ever offer patients counseling for alternatives if they cannot afford this?
  - Yes we do
- As there is no data that suggests Injectable vs oral vitamin b6 is better, how can it be justified to charge the patients more money for this?
  - We always offer for the patient to start with the commercially available drug and they can move to the compounded version if needed.
- Have you had any patients where it wasn't successful even with the injectable Vitamin B6?
  - Not that often, usually the doctors will further adjust the dosing and that helps
- Do you do lyophilization at your pharmacy?
  - We did, but as of this month we are stopped doing so.
- What is your Max BUDs?
  - 45 days refrigerated after sterility and endotoxin is completed
- How do you sterilize your products?
  - Filtration
- Do you complete USP sterility and endotoxin testing on all your batches?
  - Yes
- Is there ever an instance where the medication does not get to the patient?
  - No, we have had patients or providers who have asked for replacement because it was left out side, but not an issue of the medications getting to the patient.

**Action:** T. FENSKY made a motion to defer the application until such time as Board staff receives documentation of the updated versions of the order forms that were submitted, documentation which states that Promise Pharmacy is in full compliance with the previous inspection, documentation of semaglutide clinical data when compounded with vitamin b6, and confirmation that Promise Pharmacy is in compliance with section 503A of the FD&C act; seconded by D. BARNES and voted unanimously by roll call of those present to approve the motion.

---

## TOPIC VII:

## FILE REVIEW

Case #1/CASE-2025-2146

PHA-2025-0066

Apotheco Pharmacy Newton. LLC, DS90339

Time: 09:52 AM

RECUSAL: NONE

DISCUSSION: J. TRAN presented and summarized the investigative report that pertained to this matter.

- During a retail compliance inspection conducted on 06/24/2025, the Investigator observed PTT Andrade working with an expired license.
- MOR Jamal noted that PTT Andrade immediately requested an extension of her PTT license on 06/24/25 and resumed her PTT duties that same day.
- MOR Jamal admitted that both he and the PTT were responsible for the oversight. He noted that PTT Andrade was relatively new and had a 2 month leave of absence during her first year working as contributing factors.

- MOR Jamal also stated that the increased volume at the Pharmacy and a pharmacist's LOA contributed to his failure to ensure all staff were properly licensed.
- MOR Jamal noted that between 06/12/2025 through 06/24/2025, PTT Andrade worked 36 hours with an expired license.
- MOR Jamal stated that as corrective action the MOR will review the license expiration dates for all employees on a daily basis and all employees have been retrained on their obligations to maintain their license.

ACTION: Motion by D. BARNES, seconded by M. SCIARAFFA, and voted unanimously by those present, to refer the matter (PHA-2025-0066), to the Office of Prosecution for the issuance of an order to show cause and to authorize resolution of the matter by a consent agreement for REPRIMAND.

---

Case #2/CASE-2025-1929

PHA-2025-0075

Empower Pharma, NO00019

Time: 09:54 AM

RECUSAL: NONE

DISCUSSION: G. MELTON presented and summarized the investigative report that pertained to this matter.

- On 04/16/2025, BORP received timely notification from Empower regarding receipt of an FDA Warning Letter on 04/02/2025. The Warning Letter was issued after an FDA inspection conducted from 08/01/2024 to 08/28/2024 and subsequent FDA Form issued on 08/28/2024. The Warning Letter described that Empower failed to meet condition of section 503B for preparation, packaging, or holding of adulterated drug products, CGMP violations, preparation of unapproved drugs, inadequate corrective action plan, and repeat CGMP violations. Of note, FDA had not issued a closing letter for this matter as of 10/29/2025.
- In response to the complaint, Empower asserted that no basis existed for BORP to discipline based on the Warning Letter for the following reasons. First, Empower argued that "the Warning Letter is not final agency action and is not a determination of Empower's regulatory compliance; therefore, the Warning Letter's interim findings do not create a basis for action against Empower's Massachusetts permit..."
- Next, Empower argued that "there is no need to discipline Empower because Empower promptly implemented corrective actions, where necessary, in response to the Warning Letter." Empower then noted the following corrective action: (1) Hired Three External Consultants for Batch Certification and Random Floor Audits, (2) Expanded Quality Department, (3) Updated Smoke Studies, (4) Improved Investigation Procedures, (5) Enhanced EM Investigation Template, (6) Created Cleaning Validation Benchmarks, and (7) Implemented Cleaning Validations for Pellet Products.

ACTION: Motion by M. SCIARAFFA, seconded by C. BELISLE, and voted unanimously by those present, with the exception of a NAY vote by J. Rocchio, to refer the matter (PHA-2025-0075), to the Office of Prosecution for the issuance of an order to show cause and to authorize resolution of the matter by a consent agreement for REPRIMAND.

---

RECUSAL: NONE

DISCUSSION: G. MELTON presented and summarized the investigative report that pertained to this matter.

- On 07/18/2025, West 35th submitted an untimely notification to BORP that the pharmacy was fined \$5,000.00 in a summary order issued by KS BOP on 05/01/2025 for failing to submit reports to KS's version of PMP.
- West 35th acknowledged that the pharmacy failed to notify BORP about the KS BOP discipline within 14 days. West 35th explained that "the delay was due to a misunderstanding that disciplinary actions are to be reported upon renewal."
- CA: West 35th retrained its staff on notification requirements and retained outside counsel to assist the pharmacy with updating applicable policies and procedures to ensure timely notice of disciplinary action is provided to state boards. In addition, West 45th assured BORP that "all state boards" were notified about the KS BOP discipline.

ACTION: Motion by K. THORNELL, seconded by S. DINNO, and voted unanimously by those present, with the exception of T. FENSKY who abstained, to DISMISS the matter (PHA-2025-0085), No Discipline Warranted, Remediation Complete.

---

RECUSAL: NONE

DISCUSSION: G. MELTON presented and summarized the investigative report that pertained to this matter.

- On 08/13/2025, Partners was cited for multiple inspectional deficiencies during a sterile compounding inspection including records which were not readily retrievable and environmental monitoring which did not comply with USP 797. Upon BORP request, Partners agreed to cease sterile compounding and not resume compounding without BORP approval. Partners had yet to resume compounding as of 11/14/2025.
- CA: MOR Vogel first pledged, "I, the Manager of Record (MOR), have been given access to PharmaCerts portal to monitor ongoing compliance studies requisite for Certification and Environmental monitoring. I will print 2 copies of said finalized reporting. One copy will be kept in the IV Department in a book labeled 'CERTS/EM Reports'. The second copy will be filed in the MOR's office."
- MOR Vogel next indicated that "Partners of Massachusetts, has now set up a pre-payment plan with our vendor, PharmaCerts to ensure environmental monitoring and certification is done monthly and every 6 months respectively." Lastly, MOR Vogel reiterated that "[she] added recurring tasks within Simpli797 to ensure consistency in monitoring."

ACTION: Motion by C. BELISLE, seconded by M. SCIARAFFA, and voted unanimously by those present, to DEFER the vote (PHA-2025-0094).

---

Case #5/CASE-2025-2304

PHA-2025-0072

CVS #209, DS3597

Time: 10:03 AM

RECUSAL: J. ROCCHIO recused and was not present for the vote or discussion in this matter.

DISCUSSION: G. MELTON presented and summarized the investigative report that pertained to this matter.

- On 07/03/2025, BORP learned that CVS 209 refused to fill a prescription for a Schedule VI (non-federally) controlled substance, methimazole, issued to a feline patient unless Dr. O'Dell provided her DEA registration number in violation of recognized standards of practice.
- CVS Health Pharmacy Regulatory Affairs Senior Analyst Stephaney Furtado responded on behalf of the pharmacy. Analyst Furtado wrote, "Reaching out regarding the above noted OPP request for store 00209. The team has no response to provide as they state the current team has no knowledge of this incident. Additionally, there is no employee named Lucy associated with the team."
- CA: Analyst Furtado indicated that "the team did discuss this event however and ensuring all are aware of the requirements for a prescribing vet."

ACTION: Motion by K. THORNELL, seconded by R. MORELLI, and voted unanimously by those present, to DISMISS the matter (PHA-2025-0072), Insufficient Evidence.

---

Case #6/CASE-2025-2306

PHA-2025-0081

CVS #17655, DS89999

Time: 10:05 AM

RECUSAL: J. ROCCHIO recused and was not present for the vote or discussion in this matter.

DISCUSSION: J. TRAN presented and summarized the investigative report that pertained to this matter.

- During a retail compliance inspection conducted on 7/15/2025, the Investigator observed that the licensee does not prepare non-complex, non-sterile compounded preparations customary to the community needs.
- In response, MOR Hwang admitted that he would refer patients to a nearby retail pharmacy that specializes in compounding. He indicated that he was unaware of the most current process since the withdrawal and recall of commercially available compounding kits. He had a counseling session with the District Leader to follow up on how to compound "magic mouthwash".
- CVS' internal policy states that the MOR serves as the "designated person responsible and accountable for the performance and operation of the facility and personnel in the preparation of nonsterile compounded preparations." This included training.
- MOR Hwang noted that all pharmacy colleagues are now aware of the location of the compounding log, compounding materials, and reviewed all necessary MA compounding guidelines and ordered the required compounding ingredients.

**ACTION:** Motion by R. MORELLI, seconded by D. BARNES, and voted unanimously by those present, to DISMISS the matter (PHA-2025-0081), No Discipline Warranted, Remediation Complete.

---

**Topic VIII:** **Executive Session Call to Order:** **TIME: 10:08 AM**

By: President S. Ahmed reads the executive session language and requests a motion to enter executive session.

**ACTION:** Motion by S. DINNO seconded by R. MORELLI, voted unanimously by roll call to enter executive session #1.

---

**Topic IX:** **Adjudicatory Session** **TIME: 10:40 AM**

By: President S. Ahmed request a motion to enter Adjudicatory Session.

**ACTION:** At 10:40 AM S. SCIARAFFA seconded by K. THORNELL and voted unanimously by all those present to enter the Adjudicatory Session by roll call vote.

---

**Topic X:** **65C Sessions MGL c. 112 section 65C** **TIME: 10:47 AM**

By: President S. Ahmed request a motion to enter M.G.L 65 c Session.

**ACTION:** Motion by M. SCIARAFFA, seconded by K. THORNELL and voted unanimously by all those present to enter M.G.L. chapter 65 C Session by roll call vote.

---

**Topic XI:** **ADJOURNMENT OF MEETING** **TIME: 12:38 PM**

**ACTION:** Motion by M. SCIARAFFA seconded K. THORNELL and voted unanimously by those present, to adjourn the meeting by roll call vote.

---

**EXHIBITS USED DURING THE OPEN SESSION OF THE MEETING**

1. December 4, 2025, Agenda
2. November 6, 2025, Board Minutes
3. Licensure Policy 13-01 Report
4. Monthly Probation Report
5. BDR Licensure Report pursuant Policy 14-02
6. Cure-Aid Pharmacy – New Retail Pharmacy
7. Medwiz of Mass, LLC – Petition for Waiver
8. Promise Pharmacy – Non-Resident Sterile Compounding
9. MedMinder Pharmacy – Waiver performance data
10. XeCare, LLC – Non-Resident Complex Non- Sterile (Deferred)
11. PHA-2025-0066 Apotheco Pharmacy Newton, LLC
12. PHA-2025-0075 Empower Pharma,
13. PHA-2025-85 West 35<sup>th</sup> Apothecary
14. PHA-2025-0094 Partners of MA, LLC
15. PHA-2025-0072 CVS #209 (deferred)
16. PHA-2025-0081 CVS 317655